Hims & Hers Health stock forecast: FDA GLP-1 warning
Hims & Hers Health is a US telehealth company. In August 2026, the FDA issued a warning concerning unapproved compounded GLP-1 weight-loss drugs. Explore third-party HIMS price targets and technical analysis. Past performance is not a reliable indicator of future results.
Hims & Hers Health, Inc. (HIMS) last traded around $28.20 in early trading at 10:55am UTC on 9 September 2026, near the upper end of its $27.62–$28.23 intraday range. Past performance is not a reliable indicator of future results.
Recent attention has centred on a Food and Drug Administration (FDA) warning over unapproved compounded GLP-1 weight-loss drugs (Yahoo Finance, 1 September 2026), alongside Hims & Hers' expansion into Australia's men's health market (TradingView, 2 September 2026). The company also faces a US Federal Trade Commission lawsuit alleging it shared users' health data with advertisers, which has prompted several securities class-action filings (Simply Wall St, 5 September 2026).
Third-party Hims & Hers outlook: FDA scrutiny and growth in focus
As of 9 September 2026, third-party Hims & Hers Health stock predictions show a range of 12-month outcomes, reflecting different views on growth, margins and regulatory risk.
Barclays (individual broker forecast)
Barclays cut its HIMS price target to $35 from $39 while maintaining an overweight rating. The revision reflects margin pressure alongside continued revenue growth (MarketBeat, 21 August 2026).
Truist Financial (individual broker forecast)
Truist raised its price target to $32 from $27 while assigning a hold rating, citing proprietary card-spending data in support of its revised estimate (MarketBeat, 24 August 2026).
MarketBeat (consensus overview)
MarketBeat's aggregation of 16 brokerages shows an average 12-month target of $32.50 and a consensus hold rating, comprising four buy, 11 hold and one sell recommendation (MarketBeat, 2 September 2026).
TickerNerd (consensus overview)
TickerNerd reports a median 12-month target of $31 from 15 Wall Street analysts, with estimates ranging from $23–$42 (TickerNerd, 4 September 2026).
Financhill (quantitative forecast)
Financhill's proprietary model projects a 52-week price of $38.92, while the same page cites a Wall Street consensus target of $31.23 from 13 analysts. The difference reflects the use of separate forecasting methods (Financhill, 3 September 2026).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
Hims & Hers Health: latest and upcoming earnings
Hims & Hers Health reported second-quarter 2026 results on 10 August. Revenue rose 38% year on year to around $753.2m, while subscribers increased 19% to nearly 2.9 million (Hims & Hers, 10 August 2026).
The company posted a net loss of $86.3m, compared with net income of $42.5m a year earlier, while gross margin narrowed to 64% from 76%. Adjusted EBITDA fell to $60.3m from $82.2m. Hims & Hers raised full-year revenue guidance to $3.1bn–$3.3bn from $2.8bn–$3bn, with adjusted EBITDA guidance of $275m–$325m. Third-quarter revenue guidance stands at $880m–$900m.
Hims & Hers has not confirmed its next earnings date. Based on previous reporting patterns, MarketBeat estimates third-quarter results could be released around 9 November (MarketBeat, 10 August 2026).
HIMS stock price: technical overview
As of 10:55am UTC on 9 September 2026, the HIMS stock price trades below its 20-, 50- and 100-day simple moving averages at roughly $30, $31 and $30, while remaining close to its 200-day average near $28, according to TradingView. The 14-day relative strength index (RSI) sits near 45, within neutral territory, while the average directional index (ADX) near 11 indicates limited trend strength.
Higher technical references include $30.47 and $33.56, with further levels around $34.84 and $37.55. Below the latest price, the 200-day moving average near $28 provides a nearby reference, followed by S1 around $26.49.
A rise could bring higher levels into focus, while a move lower could shift attention towards S1. These are technical reference points rather than predictions (TradingView, 9 September 2026).
This is technical analysis for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any instrument.
Hims & Hers Health share price history (2024–2026)
HIMS’s stock price closed at $14.53 on 10 September 2024 before rising through late 2024 and early 2025, reaching $73.09 on 19 February 2025 during a period of growing interest in GLP-1 weight-loss treatments.
Shares then moved lower amid supply and partnership uncertainty before reaching $70.59 on 31 July 2025. The stock subsequently fell into 2026, reaching $15.27 on 6 March as regulatory and margin concerns coincided with weaker sentiment.
HIMS recovered above $35 by mid-2026 before moving lower again amid FTC litigation and FDA scrutiny over compounded GLP-1 products. The stock closed at $28.18 on 9 September 2026, down around 16% year to date but above its September 2024 level.
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Hims & Hers Health (HIMS): Capital.com analyst view
Hims & Hers shares have moved sharply in both directions over the past two years, alongside rapid growth and periods of regulatory scrutiny. Subscriber growth, higher revenue and international expansion may support sentiment, while weaker margins, litigation and further FDA or FTC action could weigh on the shares.
The balance between growth and regulatory risk remains important to the outlook. Stronger financial performance or expansion could support the price, while weaker execution or additional legal and regulatory pressure could push it lower. These are potential influences rather than a forecast of future direction.
Capital.com’s client sentiment for Hims & Hers Health CFDs
As of 9 September 2026, Capital.com client positioning in Hims & Hers Health CFDs is weighted towards long positions, with 96.9% long and 3.1% short. This reflects open positions at the time of measurement rather than future price direction and can change.
Summary – Hims & Hers Health 2026
- As of 10:55am UTC on 9 September 2026, HIMS traded near $28.20, within an intraday range of $27.62–$28.23.
- According to TradingView data, the share price was below its 20-, 50- and 100-day moving averages and close to its 200-day average, with RSI near 45 and ADX near 11.
- Key factors include subscriber and revenue growth, margin pressure, GLP-1 developments and FDA and FTC scrutiny.
- Growth and international expansion may support sentiment, while weaker margins or further regulatory and legal pressure could weigh on the shares.
- Recent attention centres on the FDA warning over compounded GLP-1 products, Australian expansion and securities class-action filings following the FTC lawsuit.
Past performance is not a reliable indicator of future results.
FAQ
Who owns the most Hims & Hers Health stock?
This article does not identify Hims & Hers Health's largest shareholder or provide a breakdown of its ownership structure. Instead, it focuses on recent share-price performance, earnings, subscriber growth, regulatory developments and third-party forecasts. Ownership can change as institutional and other investors adjust their holdings, so current shareholder disclosures would need to be checked separately when assessing who holds the largest stake in Hims & Hers Health.
What is the five-year Hims & Hers Health share price forecast?
The article does not provide a five-year HIMS stock forecast. The third-party estimates covered here mainly focus on 12-month targets, ranging from $23–$42. Longer-term forecasts carry greater uncertainty because subscriber growth, margins, regulation, litigation and the company's expansion strategy can change materially over several years. These estimates should therefore be treated as scenarios rather than reliable indications of where the HIMS share price may trade in five years.
Is Hims & Hers Health a good stock to buy?
This article does not classify Hims & Hers Health as a good or bad stock to buy. Subscriber growth, higher revenue and international expansion may support sentiment, while weaker margins, litigation and further FDA or FTC action could weigh on the shares. Third-party analyst views also differ, with hold the most common consensus rating. These factors provide context for assessing HIMS but do not amount to an investment recommendation.
Could Hims & Hers Health stock go up or down?
Yes. Hims & Hers Health shares can move in either direction as company-specific and wider market conditions change. Stronger subscriber growth, revenue or international expansion could support sentiment, while weaker margins, regulatory action, litigation or disappointing execution could weigh on the stock. Technical levels may also influence short-term trading activity, but they are reference points rather than reliable predictions of future price movements.
Should I invest in Hims & Hers Health stock?
Whether Hims & Hers Health shares are suitable for you depends on your circumstances, objectives and tolerance for risk, and this article does not provide investment advice or a personal recommendation. Factors to consider include subscriber and revenue growth, margins, GLP-1 developments, international expansion and ongoing FDA and FTC scrutiny. Each could influence the share price positively or negatively, while unexpected legal, regulatory or financial developments may change the outlook.
Can I trade Hims & Hers Health CFDs on Capital.com?
Yes, you can trade Hims & Hers Health CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.